Nathan B. Webb
As the life sciences industry continues to emerge as a major source of innovation and catalyst for economic growth, many biotechnology companies are encountering significant challenges in building and maintaining a strong patent portfolio. The spectre of a “patent cliff” looms over many blockbuster drug patents set to expire in the coming years, whilst generic products continue their surge onto the market, forcing companies to invest heavily in the research and development of new products. Complicating companies’ efforts to obtain patent protection on these innovations, however, are the evolving guidelines dictating which discoveries are even eligible for patentability.
To read the entire article, click the PDF below:
